Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04336397 · ClinicalTrials.gov registry record · NA
Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People
A NA study, sponsored by Alaska Native Tribal Health Consortium.
- Completed
- Registry status
- NA
- Development phase
- 2,029
- Enrollment target
NCT04336397: Completed NA study, sponsored by Alaska Native Tribal Health Consortium.
NCT04336397 is a NA study that has completed, run by Alaska Native Tribal Health Consortium. The registered enrollment target is 2,029 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04336397, a NA study, has completed, sponsored by Alaska Native Tribal Health Consortium.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,029 participants
- Enrollment target
Study Summary
Only 59% of Alaska Native people have been adequately screened for colorectal cancer (CRC) despite having the highest reported incidence of CRC in the world. A new at-home multi-target stool DNA screening test (MT-sDNA; Cologuard®) with high sensitivity for pre-cancerous polyps and CRC is now available. MT-sDNA has not been tested for feasibility or acceptability within the Alaska tribal health care delivery system, and it is unknown whether use of this new test will increase Alaska Native CRC screening rates. The long-term study goal is to improve screening and reduce CRC-attributable mortality. The objective of this application is to test the effectiveness of MT-sDNA for increasing CRC screening in Alaska Native communities using a mixed methods, community-based participatory research (CBPR) approach. The study will be conducted in collaboration with regional Tribal health organizations responsible for providing health care to geographically remote Alaska Native communities. Although the proposed implementation strategy is evidence-informed and promising, it is novel in that MT-sDNA has not been evaluated in the tribal health setting or among rural/remote populations. Using the RE-AIM Model, the research will be multi-level, examining influence on patients, providers, and tribal health organizations (THOs). This research study will pursue two specific aims: (1) Identify patient-, provider-, and system-level factors associated with CRC screening preferences, uptake, and follow-up; and (2) test the effectiveness of graded intensity MT-sDNA intervention in the Alaska Native community setting. For the first aim, focus groups with Alaska Native people who are not adherent to CRC screening guidelines and interviews with healthcare providers will be used to identify factors for future intervention. For the second aim, a three-arm cluster randomized controlled trial (high intensity with patient navigation, medium intensity with mailed reminders, usual care) will provide e
Primary Outcome
Incident CRC screening episode defined as having at least one of the following within 1 year of follow-up after randomization and intervention: colonoscopy; MT-sDNA with a negative result; or MT-sDNA with a positive result followed by a colonoscopy within 1 year.
Interventions
- DIAGNOSTIC_TEST Colonoscopy
- DIAGNOSTIC_TEST Multi-target stool DNA test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,029 participants |
| Start Date | 2021-04-29 |
| Est. Completion | 2024-09-15 |
| Phase | NA |
What the finished NCT04336397 record still lists
NCT04336397 is an interventional study that assigns participants to a tested intervention. Its 2,029 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (45% higher).
The record links to 0 conditions, and to 2 interventions - of which Colonoscopy is the first listed.
NCT04336397 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04336397 about?
NCT04336397 is a clinical study titled "Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People". Only 59% of Alaska Native people have been adequately screened for colorectal cancer (CRC) despite having the highest reported incidence of CRC in the world. A new at-home multi-target stool DNA screening test (MT-sDNA; Cologuard®) with high sensitivity for pre-cancerous polyps and CRC is now availa...
What is the current status of trial NCT04336397?
This trial is currently completed. It is a NA study. The enrollment target is 2,029 participants. The study started on 2021-04-29. Estimated completion is 2024-09-15.
What interventions are being tested in trial NCT04336397?
The interventions under investigation include: Colonoscopy (DIAGNOSTIC_TEST), Multi-target stool DNA test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04336397?
This trial is sponsored by Alaska Native Tribal Health Consortium, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04336397's enrollment target sits among peer trials
2,029 52nd of 2000 higher than 1,949 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04216732 · 2,030 participants
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
- NCT05625659 · 2,032 participants · NA
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- NCT05059444 · 2,020 participants
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- NCT06825897 · 2,039 participants · NA
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI